RPRM and neoplasm: In addition, we validated the capacity of the optimized ATF platforms to reactivate a novel TSG, tp53 dependent G2 arrest mediator candidate, REPRIMO [54–56], which has been proposed to have tumor suppressive functions in gastric [57, 58] and thyroid cancers among others [59].